News stories about STAAR Surgical (NASDAQ:STAA) have trended somewhat positive this week, according to Accern Sentiment Analysis. Accern scores the sentiment of press coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. STAAR Surgical earned a media sentiment score of 0.16 on Accern’s scale. Accern also gave media headlines about the medical instruments supplier an impact score of 45.9721524306355 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
A number of analysts recently issued reports on the stock. Canaccord Genuity increased their price target on shares of STAAR Surgical from $17.50 to $20.00 and gave the stock a “buy” rating in a report on Friday, November 17th. Zacks Investment Research downgraded shares of STAAR Surgical from a “buy” rating to a “hold” rating in a report on Wednesday, October 11th. BidaskClub downgraded shares of STAAR Surgical from a “sell” rating to a “strong sell” rating in a report on Saturday, January 6th. Finally, Benchmark reaffirmed a “buy” rating and set a $21.00 price objective on shares of STAAR Surgical in a report on Monday, November 20th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and two have assigned a buy rating to the company. The company currently has a consensus rating of “Hold” and an average target price of $17.67.
Shares of STAAR Surgical (NASDAQ:STAA) opened at $16.15 on Friday. STAAR Surgical has a 12-month low of $8.95 and a 12-month high of $17.60. The stock has a market cap of $658.63, a PE ratio of -323.00 and a beta of 1.19. The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.72 and a current ratio of 2.24.
STAAR Surgical Company Profile
STAAR Surgical Company designs, develops, manufactures and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. It operates in the ophthalmic surgical market segment. Its principal products are intraocular lenses used in cataract surgery and implantable collamer lenses used in refractive surgery.
Receive News & Ratings for STAAR Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STAAR Surgical and related companies with MarketBeat.com's FREE daily email newsletter.